Erratum to 2.6 Ubiquitin-Like Activity of shprh Protein and Ovarian Cancer (Curr Oncol, (2012), 19, (324-8), 10.3747/co.19.1175);Ubiquitin pathway and ovarian cancer

Current Oncology

Volumn 19, Issue 6, 2012, Pages 324-328

  Rao, Z ^a   Ding, Y ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Gene expression; Ovarian cancer; Protein degradation; Therapy; Ubiquitin

Indexed keywords

CISPLATIN; CYCLINE; LACTACYSTIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEASOME; PROTEIN P53; RPN13 PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; UBIQUITIN; UNCLASSIFIED DRUG;

CELL CYCLE; DRUG TARGETING; ERBB2 GENE; GENE EXPRESSION; GENE FUNCTION; HUMAN; NONHUMAN; OVARY CANCER; P53 GENE; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84870753764     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1603     Document Type: Erratum

References (32)

1. Yamamura M, Hirai T, Yamaguchi Y. Proteasome inhibitor [Japanese]. Nippon Rinsho 2010;68:1079-84.
2. Ohta T, Fukuda M. Ubiquitin and breast cancer. Oncogene 2004;23:2079-88.
3. Brzovic PS, Lissounov A, Christensen DE, Hoyt DW, Klevit RE. A UbcH5/ubiquitin noncovalent complex is required for processive brca1-directed ubiquitination. Mol Cell 2006;21:873-80.
4. Tenev T, Marani M, McNeish I, Lemoine NR. Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. Cell Death Differ 2001;8:256-64.
5. Tania M, Khan MA, Song Y. Association of lipid metabolism with ovarian cancer. Curr Oncol 2010;17:6-11.
6. Friedenson B. The brca1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007;7:152.
7. Starita LM, Parvin JD. The multiple nuclear functions of brca1: transcription, ubiquitination and dna repair. Curr Opin Cell Biol 2003;15:345-50.
8. Kim H, Chen J, Yu X. Ubiquitin-binding protein rap80 mediates brca1-dependent dna damage response. Science 2007;316:1202-5.
9. Choi YH. Proteasome-mediated degradation of brca1 protein in MCF-7 human breast cancer cells. Int J Oncol 2001;19:687-93.
10. Hayami R, Sato K, Wu W, et al. Down-regulation of brca1-bard1 ubiquitin ligase by cdk2. Cancer Res 2005;65:6-10.
11. Shakya R, Reid LJ, Reczek CR, et al. BRCA1 tumor suppression depends on brct phosphoprotein binding, but not its E3 ligase activity. Science 2011;334:525-8.
12. Jensen DE, Proctor M, Marquis ST, et al. Bap1: a novel ubiquitin hydrolase which binds to the brca1 ring finger and enhances brca1-mediated cell growth suppression. Oncogene 1998;16:1097-112.
13. Schoenfeld AR, Apgar S, Dolios G, Wang R, Aaronson SA. BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to dna damage. Mol Cell Biol 2004;24:7444-55.
14. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
15. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005;4:677-85.
16. Kohno M, Pouyssegur J. Targeting the erk signaling pathway in cancer therapy. Ann Med 2006;38:200-11.
17. Steinmetz R, Wagoner HA, Zeng P, et al. Mechanisms regulating the constitutive activation of the extracellular signalregulated kinase (erk) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for erk1/2 on cancer cell proliferation. Mol Endocrinol 2004;18:2570-82.
18. Fürthauer M, Lin W, Ang SL, Thisse B, Thisse C. Sef is a feedback-induced antagonist of Ras/mapk-mediated fgf signalling. Nat Cell Biol 2002;4:170-4.
19. Eblaghie MC, Lunn JS, Dickinson RJ, et al. Negative feedback regulation of fgf signaling levels by Pyst1/mkp3 in chick embryos. Curr Biol 2003;13:1009-18.
20. Chan DW, Liu VW, Tsao GS, et al. Loss of mkp3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 2008;29:1742-50.
21. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261-91.
22. Xu G, Bernaudo S, Fu G, Lee DY, Yang BB, Peng C. Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell 2008;19:4968-79.
23. Brandt Y, Mitchell T, Wu Y, Hartley RS. Developmental downregulation of Xenopus cyclin E is phosphorylation and nuclear import dependent and is mediated by ubiquitination. Dev Biol 2011;355:65-76.
24. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase chip mediates a degradative pathway for c-ErbB2/NEU. Proc Natl Acad Sci U S A 2002;99:12847-52.
25. Allende-Vega N, Saville MK. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy. Semin Cancer Biol 2010;20:29-39.
26. Hwang IY, Baguley BC, Ching LM, Gilchrist CA. The ubiquitinproteasome system is inhibited by p53 protein expression in human ovarian cancer cells. Cancer Lett 2010;294:82-90.
27. Unk I, Hajdú I, Fátyol K, et al. Human shprh is a ubiquitin ligase for Mms2-Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen. Proc Natl Acad Sci U S A 2006;103:18107-12.
28. Li QQ, Yunmbam MK, Zhong X, et al. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cell Mol Biol (Noisy-le-grand) 2001;47:OL61-72.
29. Zhang P, Gao W, Li H, Reed E, Chen F. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. Biochem Biophys Res Commun 2005;328:567-72.
30. Bazzaro M, Lin Z, Santillan A, et al. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008;14:7340-7.
31. Uddin S, Ahmed M, Hussain AR, et al. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Lab Invest 2009;89:1115-27.
32. Al-Shami A, Jhaver KG, Vogel P, et al. Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development. PLoS One 2010;5:e13654.